DAPA-HF One Year on: What Have You Missed?
Published: 31 July 2020
-
Views:
48
-
Likes:
7
-
Views:
48
-
Likes:
7
-
10m 9s
-
11m 57sPart 1 Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF John JV McMurray
-
12m 26sPart 2 Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF Piotr Ponikowski
-
11m 7sPart 3 DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF Scott Solomon
Overview
This session was part of the 1st e-SPACE Heart Failure Meeting held virtually on July 11-14th 2020 and focused upon analysing the DAPA-HF SGLT2 randomised clinical trial and subsequent sub-analysis data that been published over the last 12 months.
Agenda
- Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF - John McMurray (University of Glasgow, Glasgow, UK)
- Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF - Piotr Ponikowski (Wroclaw Medical University, Wroclaw, PL)
- DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF- Scott Solomon (Brigham & Women’s Hospital, Boston, US)
- Impact of Dapagliflozin Treatment on KCCQ - Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US)
- Dapagliflozin and Diuretic Use in Patients With HFrEF - Alice Jackson (University of Glasgow, Glasgow, UK)
More from this programme
Part 1
Effect of Dapagliflozin on Outpatient Worsening in Patients with HFrEF
Part 2
Benefit of Dapagliflozin on First and Repeat Events in Patients with HFrEF
Part 3
DAPA-HF: Effect of Dapagliflozin on Renal Outcomes in HFrEF
Part 4
Impact of Dapagliflozin Treatment on KCCQ
Part 5
Dapagliflozin and Diuretic Use in Patients With HFrEF
Faculty Biographies
Mikhail Kosiborod
Cardiologist
Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes.